The estimated Net Worth of Michael M Tarnow is at least $3.18 Million dollars as of 18 May 2021. Mr. Tarnow owns over 8,229 units of Xenon Pharmaceuticals Inc stock worth over $3,012,458 and over the last 10 years he sold XENE stock worth over $0. In addition, he makes $169,615 as Independent Chairman of the Board at Xenon Pharmaceuticals Inc.
Michael has made over 13 trades of the Xenon Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 8,229 units of XENE stock worth $30,612 on 18 May 2021.
The largest trade he's ever made was exercising 14,403 units of Xenon Pharmaceuticals Inc stock on 12 December 2016 worth over $46,234. On average, Michael trades about 3,279 units every 101 days since 2014. As of 18 May 2021 he still owns at least 77,942 units of Xenon Pharmaceuticals Inc stock.
You can see the complete history of Mr. Tarnow stock trades at the bottom of the page.
Michael M. Tarnow J.D. serves as Independent Chairman of the Board of the Company. Mr. Tarnow has been an advisor to and member of the boards of directors of private and public healthcare and biotechnology companies in the U.S., Canada and Europe, including Axcan Pharma, Creative Biomolecules, Inc., Caprion Pharmaceuticals Inc. and MediGene AG. He served as chair of EntreMed, Inc. (now CASI Pharmaceuticals, Inc.) a publicly-traded biotechnology company, from February 2003 to February 2009, and served as Executive Chair of EntreMed from February 2009 to January 2012. Mr. Tarnow holds a B.B.A. in Business Administration from Wayne State University and a J.D. from the University of Illinois, College of Law. Our Board believes that Mr. Tarnow is qualified to serve on our Board because of his senior management experience in the pharmaceutical industry and his knowledge and perspective of the Corporation.
As the Independent Chairman of the Board of Xenon Pharmaceuticals Inc, the total compensation of Michael Tarnow at Xenon Pharmaceuticals Inc is $169,615. There are 8 executives at Xenon Pharmaceuticals Inc getting paid more, with Simon Pimstone having the highest compensation of $2,612,720.
Michael Tarnow is 74, he's been the Independent Chairman of the Board of Xenon Pharmaceuticals Inc since . There are no older and 22 younger executives at Xenon Pharmaceuticals Inc.
Michael's mailing address filed with the SEC is 200 - 3650 GILMORE WAY, , BURNABY, A1, V5G 4W8.
Over the last 10 years, insiders at Xenon Pharmaceuticals Inc have traded over $12,977,011 worth of Xenon Pharmaceuticals Inc stock and bought 724,015 units worth $2,649,316 . The most active insiders traders include Patrick Machado, Partners L P/Ilbiotechnolog..., and Justin D. Gover. On average, Xenon Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $818,878. The most recent stock trade was executed by Elizabeth A. Garofalo on 8 March 2024, trading 3,500 units of XENE stock currently worth $64,960.
xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Xenon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: